Important note: Information in this article was accurate in May 2009. The state of the art may have changed since the publication date.
Superinfection identified in 2 out of 8 patients with unexpected viral load increases
HIV Treat Bull - 2009 May-Jun;10(5/6): 03
Simon Collins, HIV i-Base
The rate and risk of reinfection with a second strain of HIV after primary infection are unclear with most instances reported as case studies. While reinfection clearly occurs, with viral load of the transmitting partner likely to be a significant risk factor, the clinical importance of a second infection, based on current limited data, appears largely related to acquisition of a resistant strain and its impact on reducing treatment options.
A pilot study by Doyle and colleagues at UCL looked for treatment-naive patients who were at risk of reinfection from sexual exposure, who experienced a significant viral load increase (>0.5 log) during routine viral load clinic monitoring. Eight patients were indentified (all sub-type B) and phylogenetic analyses were performed on the stored and most recent samples.
In two patients, early sequences formed separate clusters to late sequences, with no evidence of viral recombination, indicating a second infection.
One patient was reinfected 5 months after his initial diagnosis during acute infection, and experienced similar seroconversion symptoms at the time of viral load increase. He also acquired syphilis and herpes in the subsequent 6 months.
A second patient had been diagnosed HIV-positive 3 years earlier and experienced no symptoms and no other STIs at the time of superinfection. He controlled both the first infection and the superinfection without HAART, with a set-point viral load of 3.5 log10 copies/mL and a stable CD4 count >1000 cells/mm3.
These two cases indicate that reinfection is unlikely to be a rare event and can occur both in the early and established disease, even in the presence of effective immune responses.
Comment
While the study conclusion is that targeted screening based upon sexual history and viral load can achieve a high detection rate and is important in the context of transmitted resistance, it is not appropriate to conclude that early HAART should be used as a public health measure between consenting HIV-positive adults who choose to use neither condoms nor treatment.
Ref: Doyle T et al. High-risk sexual behaviour and HIV-1 superinfection: an indication for early initiation of antiretroviral therapy? HIV Med. 2009 April; 10(Suppl 1):54 (abstract no. P150).
2009-05-10
IB2009-05-03
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.